Multidisciplinary Team Led by Thoracic Surgery
An anterior mediastinal mass suspicious for thymic hyperplasia or thymoma should be managed by a multidisciplinary team with a board-certified thoracic surgeon with primary focus on thoracic oncology as the key decision-maker for resectability and surgical management 1.
Core Multidisciplinary Team Composition
The NCCN 2025 guidelines explicitly mandate that all patients with likely thymic tumors be treated by a multidisciplinary team with experience in thymic malignancies 1. This team must include:
- Thoracic surgeon (with primary focus on thoracic oncology) - leads surgical decision-making
- Medical oncologist - manages systemic therapy considerations
- Radiation oncologist - evaluates need for radiotherapy
- Pathologist - provides definitive histologic diagnosis
- Diagnostic imaging specialist - characterizes lesion features
- Neurologist - evaluates for paraneoplastic syndromes (particularly myasthenia gravis)
Why Thoracic Surgery Takes the Lead
The thoracic surgeon serves as the primary specialty because:
Resectability determination is surgical: A board-certified thoracic surgeon with thoracic oncology focus must determine whether complete (R0) resection is achievable 1
Surgery is first-line for most cases: Complete surgical excision via total thymectomy is the primary oncologic goal for resectable tumors 1
Median sternotomy is standard approach: Open surgical approach through median sternotomy is recommended as standard of care 2
Initial Evaluation Algorithm
Before multidisciplinary discussion, obtain:
- CT chest with contrast - characterizes mass location, size, invasion
- FDG-PET/CT (skull base to mid-thigh) - assesses metabolic activity and metastases 1
- Tumor markers: AFP and beta-hCG to exclude germ cell tumors 1
- Pulmonary function tests - if surgery anticipated 1
Thymic epithelial tumor is likely if: well-defined anterior mediastinal mass in thymic bed, negative tumor markers, no other adenopathy, and no thyroid continuity 1.
Management Pathway Based on Resectability
Surgically Resectable Disease
- Proceed directly to surgical resection (total thymectomy with complete tumor excision) 1
- Postoperative management determined by pathology and staging
Uncertain R0 Resection
Locally Advanced or Metastatic
- Obtain tissue diagnosis via core needle biopsy first 1
- Open biopsy if core not feasible (avoid transpleural approach) 1
- Then multidisciplinary treatment planning
Critical Pitfalls to Avoid
Do not perform minimally invasive surgery (VATS) as standard approach - open median sternotomy is recommended standard of care for thymoma resection 2. Minimally invasive approaches lack long-term recurrence and survival data 1.
Do not biopsy resectable lesions - if imaging suggests resectable thymic tumor with negative germ cell markers, proceed directly to surgery rather than biopsy 1.
Avoid bilateral phrenic nerve resection - causes severe respiratory morbidity 1.
Distinguishing Hyperplasia from Thymoma
This distinction is made postoperatively by pathology, not preoperatively 3, 4. True thymic hyperplasia shows:
- Preserved corticomedullary architecture
- Scattered Hassall corpuscles
- No cytologic atypia or lobular confluence
- Normal keratin/CD3/TdT/CD1a distribution 4
Nearly 66% of true thymic hyperplasia cases are initially misdiagnosed clinically as thymoma 4, reinforcing why surgical excision with pathologic diagnosis is the standard approach rather than observation.
When Medical Oncology Leads
Medical oncology becomes primary if:
- Patient medically unfit for surgery → chemoradiation or radiation alone 2
- Metastatic disease requiring systemic therapy first
- Recurrent disease after prior resection
However, even in these scenarios, thoracic surgery remains involved for resectability reassessment after induction therapy.